DataVXACS Applied Nano MaterialsPaper
journal article·2024-11-08

Prussian Blue Nanostructure Conjugated Berberine Improves Inflammatory Response of Rheumatoid Arthritis by Suppressing Necroptosis

Yuan Wang, Fang Xu, Yixuan Wang, Xinran Hu, Baofeng Zhao, Sen Lin, Xifan Mei

ACS Applied Nano Materials· Volume 7· Issue 21
Publisher page
Source abstract

Abstract

Rheumatoid arthritis has serious consequences for human health. Drugs can relieve the symptoms of some patients, but they exert significant toxic side effects. We loaded berberine into the Prussian blue nanostructure, synthesizing BRB-PB composites. It improves photothermal properties and exhibits potent anti-inflammatory and antioxidant effects. BRB-PB composites inhibited RIPK1/RIPK3/MLKL signaling pathway activation in RA synovial tissue, suggesting a unique molecular mechanism that reduces the occurrence of necroptosis and improves RA symptoms. Rapid metabolism and excellent biocompatibility of BRB-PB composites enhanced their safety and efficacy.
Source: openalex_inverted_index · Quality: baseline

Research context

NanomaterialsBiomaterialsComposites

OpenAlex topics: Berberine and alkaloids research · Andrographolide Research and Applications · Biochemical and Structural Characterization

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology, The First Affiliated Hospital and College of Basic Medical Sciences

Jinzhou Medical University

Graduate School of Dalian Medical University

Department of Orthopedics

Jinzhou Second Hospital

Third Affiliated Hospital of Jinzhou Medical University

Liaoning Provincial Collaborative Innovation Center of Medical Testing and Drug Development, Liaoning Provincial Key Laboratory of Medical Tissue Engineering

Liaoning Provincial Clinical Research Center for Bone Tissue Engineering

Liaoning Vocational College of Medicine

Funding

National Natural Science Foundation of China

References (32)

Show source-provided references
1. 10.3390/cells1011285710.3390/cells10112857 ↗
2. 10.1016/S0140-6736(16)30173-810.1016/S0140-6736(16)30173-8 ↗
3. 10.1016/j.rdc.2022.02.01010.1016/j.rdc.2022.02.010 ↗
4. 10.3390/ijms2302090510.3390/ijms23020905 ↗
5. 10.1016/j.mtbio.2022.10033110.1016/j.mtbio.2022.100331 ↗
6. 10.1302/2046-3758.122.BJR-2022-0269.R110.1302/2046-3758.122.BJR-2022-0269.R1 ↗
7. 10.1016/j.intimp.2023.11102410.1016/j.intimp.2023.111024 ↗
8. 10.1016/j.phymed.2023.15525510.1016/j.phymed.2023.155255 ↗
9. 10.1016/j.phrs.2021.10566710.1016/j.phrs.2021.105667 ↗
10. 10.1111/jcmm.1580310.1111/jcmm.15803 ↗
11. 10.2147/JIR.S33762010.2147/JIR.S337620 ↗
12. 10.1007/s40820-020-0410-x10.1007/s40820-020-0410-x ↗
13. 10.1021/acsanm.4c0136310.1021/acsanm.4c01363 ↗
14. 10.1007/s12274-022-5255-910.1007/s12274-022-5255-9 ↗
15. 10.3390/pharmaceutics1509228210.3390/pharmaceutics15092282 ↗
16. 10.1016/j.drudis.2020.05.01410.1016/j.drudis.2020.05.014 ↗
17. 10.1038/s41467-019-12429-610.1038/s41467-019-12429-6 ↗
18. 10.1016/j.biomaterials.2019.11930110.1016/j.biomaterials.2019.119301 ↗
19. 10.1016/j.mattod.2020.12.00510.1016/j.mattod.2020.12.005 ↗
20. 10.1039/D1BM01796A10.1039/D1BM01796A ↗
21. 10.1021/acsami.8b1034510.1021/acsami.8b10345 ↗
22. 10.1097/BOR.0b013e328337c95a10.1097/BOR.0b013e328337c95a ↗
23. 10.1002/art.4267410.1002/art.42674 ↗
24. Dong X. H. · American journal of translational research · 2019 · 11 · 499
25. 10.1111/acel.1351210.1111/acel.13512 ↗
26. 10.1164/rccm.202009-3442OC10.1164/rccm.202009-3442OC ↗
27. 10.3390/biom1010143110.3390/biom10101431 ↗
28. 10.1038/s41419-020-03365-110.1038/s41419-020-03365-1 ↗
29. 10.1038/srep3461710.1038/srep34617 ↗
30. 10.1136/annrheumdis-2018-21478310.1136/annrheumdis-2018-214783 ↗
31. 10.1038/s41423-020-00630-310.1038/s41423-020-00630-3 ↗
32. 10.1038/s41419-020-2328-010.1038/s41419-020-2328-0 ↗